JP2011501959A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011501959A5 JP2011501959A5 JP2010532056A JP2010532056A JP2011501959A5 JP 2011501959 A5 JP2011501959 A5 JP 2011501959A5 JP 2010532056 A JP2010532056 A JP 2010532056A JP 2010532056 A JP2010532056 A JP 2010532056A JP 2011501959 A5 JP2011501959 A5 JP 2011501959A5
- Authority
- JP
- Japan
- Prior art keywords
- albumin
- fusion protein
- seq
- fragment
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010088751 Albumins Proteins 0.000 claims 105
- 102000009027 Albumins Human genes 0.000 claims 105
- 108020001507 fusion proteins Proteins 0.000 claims 47
- 102000037865 fusion proteins Human genes 0.000 claims 47
- 150000001413 amino acids Chemical group 0.000 claims 34
- 239000012634 fragment Substances 0.000 claims 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 26
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 claims 14
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims 14
- 101800001890 Atrial natriuretic peptide Proteins 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 13
- 208000035475 disorder Diseases 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 8
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 229960003920 cocaine Drugs 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 3
- 230000000747 cardiac effect Effects 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 241000972773 Aulopiformes Species 0.000 claims 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 2
- 101000693916 Gallus gallus Albumin Proteins 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 101000930455 Ovis aries Albumin Proteins 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 208000012998 acute renal failure Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 208000008784 apnea Diseases 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 238000001784 detoxification Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 claims 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims 2
- 235000019515 salmon Nutrition 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 210000005253 yeast cell Anatomy 0.000 claims 2
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 claims 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010003162 Arterial injury Diseases 0.000 claims 1
- 102000021944 Butyrylcholinesterase Human genes 0.000 claims 1
- 108010053652 Butyrylcholinesterase Proteins 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010016803 Fluid overload Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims 1
- 206010070606 Post stroke depression Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010038540 Renal tubular necrosis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010047139 Vasoconstriction Diseases 0.000 claims 1
- 208000033774 Ventricular Remodeling Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229960002478 aldosterone Drugs 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 231100000852 glomerular disease Toxicity 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000025033 vasoconstriction Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/932,823 US20080194481A1 (en) | 2001-12-21 | 2007-10-31 | Albumin Fusion Proteins |
| PCT/US2008/012306 WO2009058322A1 (en) | 2007-10-31 | 2008-10-30 | Albumin fusion proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013233069A Division JP5856131B2 (ja) | 2007-10-31 | 2013-11-11 | アルブミン融合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011501959A JP2011501959A (ja) | 2011-01-20 |
| JP2011501959A5 true JP2011501959A5 (enExample) | 2011-12-15 |
Family
ID=40591364
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532056A Pending JP2011501959A (ja) | 2007-10-31 | 2008-10-30 | アルブミン融合タンパク質 |
| JP2013233069A Active JP5856131B2 (ja) | 2007-10-31 | 2013-11-11 | アルブミン融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013233069A Active JP5856131B2 (ja) | 2007-10-31 | 2013-11-11 | アルブミン融合タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20080194481A1 (enExample) |
| EP (1) | EP2211888A4 (enExample) |
| JP (2) | JP2011501959A (enExample) |
| AU (1) | AU2008319332B2 (enExample) |
| CA (1) | CA2703943A1 (enExample) |
| IL (1) | IL204839A0 (enExample) |
| WO (1) | WO2009058322A1 (enExample) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001079444A2 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc | Albumin fusion proteins |
| EP2277888A3 (en) | 2001-12-21 | 2011-04-27 | Human Genome Sciences, Inc. | Fusion proteins of albumin and erythropoietin |
| CA2484556A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1631496B1 (en) * | 2003-04-28 | 2014-02-26 | Medical Instill Technologies, Inc. | Container with valve assembly for filling and dispensing substances, and apparatus and method for filling |
| JP4874954B2 (ja) | 2004-04-21 | 2012-02-15 | エノビア ファーマ インコーポレイティド | 骨送達複合体ならびにタンパク質に骨を標的化させるためのその使用方法 |
| JP5566101B2 (ja) | 2006-04-24 | 2014-08-06 | メディカル・インスティル・テクノロジーズ・インコーポレイテッド | 針貫通可能かつレーザ再密閉可能な凍結乾燥装置およびこれに関連する方法 |
| US8334365B2 (en) * | 2006-06-07 | 2012-12-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| MX2011000569A (es) * | 2008-07-18 | 2011-02-23 | Novozymes Adenium Biotech As | Tratamiento de enfermedades inflamatorias con beta-defensinas de mamifero. |
| AU2009272683A1 (en) * | 2008-07-18 | 2010-01-21 | Novozymes Adenium Biotech A/S | Treatment of rheumatoid arthritis with mammal beta defensins |
| WO2010007166A2 (en) | 2008-07-18 | 2010-01-21 | Novozymes A/S | Treatment of inflammatory bowel diseases with mammal beta defensins |
| WO2011028228A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor vii compositions and methods of making and using same |
| EP2826489A1 (en) * | 2009-12-08 | 2015-01-21 | Teva Pharmaceutical Industries, Ltd. | BChE albumin fusions for the treatment of cocaine abuse |
| US8697650B2 (en) | 2010-02-16 | 2014-04-15 | Medimmune, Llc | HSA-related compositions and methods of use |
| CA2823066A1 (en) | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
| US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
| CA2826683A1 (en) * | 2011-02-15 | 2012-08-23 | Medimmune, Llc | Hsa-related compositions and methods of use |
| US20120277155A1 (en) | 2011-02-25 | 2012-11-01 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure |
| EP3189835B1 (en) * | 2011-02-28 | 2018-07-25 | National Cerebral and Cardiovascular Center | Medical agent for suppressing malignant tumor metastasis |
| HUE043894T2 (hu) | 2011-06-10 | 2019-09-30 | Bioverativ Therapeutics Inc | Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei |
| US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| SG10201601621PA (en) | 2011-06-28 | 2016-04-28 | Inhibrx Llc | Serpin fusion polypeptides and methods of use thereof |
| WO2013007596A2 (en) | 2011-07-08 | 2013-01-17 | Novozymes A/S | Oral treatment of inflammatory bowel disease |
| US20130244937A1 (en) | 2011-09-02 | 2013-09-19 | Nile Therapeutics, Inc. | Chimeric natriuretic peptide compositions and methods of preparation |
| CN104271150A (zh) | 2012-01-12 | 2015-01-07 | 比奥根艾迪克Ma公司 | 嵌合因子viii多肽及其用途 |
| ES2935489T3 (es) | 2012-02-15 | 2023-03-07 | Bioverativ Therapeutics Inc | Composiciones de factor VIII y métodos de preparación y uso de las mismas |
| CA2864126A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| IN2014MN02089A (enExample) * | 2012-03-20 | 2015-09-11 | Einstein Coll Med | |
| WO2013170636A1 (zh) * | 2012-05-18 | 2013-11-21 | 爱德迪安（北京）生物技术有限公司 | 用于糖尿病治疗的蛋白、蛋白缀合物及其应用 |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| EP2863940A4 (en) | 2012-06-08 | 2016-08-10 | Biogen Ma Inc | Chimeric clotting factors |
| AU2013270682A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Procoagulant compounds |
| NZ703366A (en) | 2012-07-11 | 2018-03-23 | Amunix Operating Inc | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
| US9827250B2 (en) * | 2012-07-31 | 2017-11-28 | Johnson & Johnson Vision Care, Inc. | Lens incorporating myopia control optics and muscarinic agents |
| WO2014063108A1 (en) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Methods of using a fixed dose of a clotting factor |
| US10772940B1 (en) | 2012-12-11 | 2020-09-15 | University Of Kentucky Research Foundation | Cocaine hydrolase-FC fusion proteins for cocaine and methods for utilizing the same |
| CA2896793A1 (en) * | 2013-01-15 | 2014-07-24 | Teva Pharmaceutical Industries Ltd. | Formulations of albu-bche, preparation and uses thereof |
| RS64664B1 (sr) | 2013-02-15 | 2023-11-30 | Bioverativ Therapeutics Inc | Gen optimizovanog faktora viii |
| AU2014217831A1 (en) | 2013-02-16 | 2015-07-16 | Albumedix Ltd. | Pharmacokinetic animal model |
| WO2014165093A2 (en) | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
| TWI788044B (zh) | 2013-03-15 | 2022-12-21 | 美商百歐維拉提夫治療公司 | 因子ｉｘ多肽調配物 |
| KR20230007555A (ko) | 2013-06-28 | 2023-01-12 | 바이오버라티브 테라퓨틱스 인크. | Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도 |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| EP4108254A1 (en) | 2013-08-14 | 2022-12-28 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
| ES2900425T3 (es) | 2013-09-25 | 2022-03-16 | Bioverativ Therapeutics Inc | Métodos de inactivación vírica en columna |
| WO2015070014A1 (en) | 2013-11-08 | 2015-05-14 | Biogen Idec Ma Inc. | Procoagulant fusion compound |
| PL3091997T3 (pl) | 2014-01-10 | 2023-01-02 | Bioverativ Therapeutics Inc. | Białka chimeryczne czynnika viii i ich zastosowania |
| WO2015168284A1 (en) * | 2014-04-30 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Albumin-bche in detoxification of neurotoxins |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| AP2017009826A0 (en) | 2014-09-26 | 2017-03-31 | Bayer Pharma AG | Stabilized adrenomedullin derivatives and use thereof |
| BR112017007765B1 (pt) | 2014-10-14 | 2023-10-03 | Halozyme, Inc | Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| ES3038086T3 (en) | 2014-12-05 | 2025-10-09 | Alexion Pharma Inc | Treating seizure with recombinant alkaline phosphatase |
| EP3250227A2 (en) | 2015-01-28 | 2017-12-06 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| MX2018001497A (es) | 2015-08-03 | 2018-05-15 | Bioverativ Therapeutics Inc | Proteinas de fusion de factor ix y metodos para producirlas y usarlas. |
| KR102644116B1 (ko) | 2015-08-17 | 2024-03-05 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼린 포스파타제의 제조 |
| US10016502B2 (en) * | 2015-08-29 | 2018-07-10 | Medrx Co., Ltd | Patch preparation containing an acid scavenger |
| US11229686B2 (en) | 2015-09-28 | 2022-01-25 | Alexion Pharmaceuticals, Inc. | Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia |
| CN105254766B (zh) * | 2015-10-26 | 2018-10-16 | 中国航天员科研训练中心 | 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用 |
| EP3368062A4 (en) | 2015-10-30 | 2019-07-03 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT |
| PH12018501628B1 (en) | 2016-02-01 | 2023-11-10 | Bioverativ Therapeutics Inc | Optimized factor viii genes |
| WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| EP3436020A4 (en) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS |
| JP7613826B2 (ja) | 2016-04-01 | 2025-01-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| EP3500289B1 (en) | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa for use in treating tracheobronchomalacia |
| WO2018082758A1 (en) | 2016-11-04 | 2018-05-11 | Aarhus Universitet | Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor |
| EP3548063A1 (en) | 2016-12-02 | 2019-10-09 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
| IL319473A (en) | 2016-12-02 | 2025-05-01 | Bioverativ Therapeutics Inc | Methods for treating hemophilic arthritis using chimeric blood clotting factors |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| WO2018112362A1 (en) | 2016-12-16 | 2018-06-21 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
| SG11201906788XA (en) | 2017-01-31 | 2019-08-27 | Bioverativ Therapeutics Inc | Factor ix fusion proteins and methods of making and using same |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| KR20240158374A (ko) | 2017-03-31 | 2024-11-04 | 알렉시온 파마슈티칼스, 인코포레이티드 | 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법 |
| EP3628009A4 (en) * | 2017-05-19 | 2021-03-24 | The Regents of The University of Colorado, A Body Corporate | COMPOSITIONS AND PROCESSES FOR IMPROVING PERCEPTION |
| NZ762100A (en) | 2017-08-09 | 2025-12-19 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
| JP2021512126A (ja) | 2018-02-01 | 2021-05-13 | バイオベラティブ セラピューティクス インコーポレイテッド | 第ｖｉｉｉ因子を発現するレンチウイルスベクターの使用 |
| EP3774861A1 (en) | 2018-03-28 | 2021-02-17 | Bristol-Myers Squibb Company | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| DK3793588T3 (da) | 2018-05-18 | 2025-06-16 | Bioverativ Therapeutics Inc | Fremgangsmåder til behandling af hæmofili a |
| WO2020010117A2 (en) | 2018-07-03 | 2020-01-09 | Bristol-Myers Squibb Company | Fgf21 formulations |
| EP3833766A1 (en) | 2018-08-09 | 2021-06-16 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| US12268733B2 (en) | 2018-08-10 | 2025-04-08 | Alexion Pharmaceuticals, Inc. | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase |
| CN113396223A (zh) | 2018-12-06 | 2021-09-14 | 比奥维拉迪维治疗股份有限公司 | 表达因子ix的慢病毒载体的用途 |
| EP3980059A1 (en) * | 2019-06-10 | 2022-04-13 | Infectious Disease Research Institute | Methods and compositions of astrovirus replicons |
| EP3986918A1 (en) | 2019-06-18 | 2022-04-27 | Bayer Aktiengesellschaft | Adrenomedullin-analogues for long-term stabilization and their use |
| CN115279896A (zh) | 2019-09-30 | 2022-11-01 | 比奥维拉迪维治疗股份有限公司 | 慢病毒载体配制品 |
| AU2020398898A1 (en) | 2019-12-09 | 2022-07-21 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| IL299333A (en) | 2020-06-24 | 2023-02-01 | Bioverativ Therapeutics Inc | Methods for the purification of viral vectors |
| CN112725305B (zh) * | 2021-01-13 | 2022-11-04 | 云南师范大学 | 热盐性敏感的菊粉酶突变体MutY119D及其制备方法 |
| BR112023016048A2 (pt) | 2021-02-12 | 2023-11-14 | Alexion Pharma Inc | Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos |
| CN119823285B (zh) * | 2025-01-09 | 2025-08-19 | 石家庄市农林科学研究院 | 一种貉α干扰素和β防御素融合蛋白及其编码基因和应用 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US5326859A (en) * | 1979-10-30 | 1994-07-05 | Juridical Foundation, Japanese Foundation For Cancer Research | DNA and recombinant plasmid |
| US5514567A (en) * | 1979-01-30 | 1996-05-07 | Juridical Foundation, Japanese Foundation For Cancer Research | DNA and recombinant plasmid |
| US4530901A (en) * | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4456748A (en) * | 1981-02-23 | 1984-06-26 | Genentech, Inc. | Hybrid human leukocyte interferons |
| WO1983002461A1 (en) * | 1982-01-19 | 1983-07-21 | Cetus Corp | Multiclass hybrid interferons |
| US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| JPS60136596A (ja) * | 1983-12-26 | 1985-07-20 | Suntory Ltd | ペプチド及びこれを有効成分とする利尿剤 |
| US4734491A (en) * | 1984-08-31 | 1988-03-29 | University Patents, Inc. | DNA sequences encoding hybrid lymphoblastoid-leukocyte human interferons |
| US4716217A (en) * | 1984-08-31 | 1987-12-29 | University Patents, Inc. | Hybrid lymphoblastoid-leukocyte human interferons |
| JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
| GB8510219D0 (en) | 1985-04-22 | 1985-05-30 | Bass Plc | Isolation of fermentation products |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| JPS6296086A (ja) | 1985-10-21 | 1987-05-02 | Agency Of Ind Science & Technol | 複合プラスミド |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5002764A (en) * | 1986-08-12 | 1991-03-26 | Schering Corporation | Treatment of actinic keratoses with alpha2 interferon |
| US5489425A (en) | 1987-06-24 | 1996-02-06 | The Dow Chemical Company | Functionalized polyamine chelants |
| US4994560A (en) | 1987-06-24 | 1991-02-19 | The Dow Chemical Company | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| ZA894792B (en) | 1988-06-24 | 1991-04-24 | Dow Chemical Co | Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates |
| US5756065A (en) | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
| ATE120457T1 (de) | 1988-06-24 | 1995-04-15 | Dow Chemical Co | Macrocyclische bifunktionelle chelatbildner, komplexe davon und ihre konjugierten antikörper. |
| US5274119A (en) | 1988-07-01 | 1993-12-28 | The Dow Chemical Company | Vicinal diols |
| JP3092811B2 (ja) | 1988-07-23 | 2000-09-25 | デルタ バイオテクノロジー リミテッド | ペプチドおよびｄｎａ配列 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5342604A (en) | 1988-10-31 | 1994-08-30 | The Dow Chemical Company | Complexes possessing ortho ligating functionality |
| US5696239A (en) | 1988-10-31 | 1997-12-09 | The Dow Chemical Company | Conjugates possessing ortho ligating functionality and complexes thereof |
| US5808003A (en) | 1989-05-26 | 1998-09-15 | Perimmune Holdings, Inc. | Polyaminocarboxylate chelators |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| GB8924021D0 (en) | 1989-10-25 | 1989-12-13 | Celltech Ltd | Recombinant dna method and vectors for the use therein |
| US5173408A (en) | 1989-11-13 | 1992-12-22 | Lange Louis George Iii | Mammalian pancreatic cholesterol esterase |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JPH07108232B2 (ja) | 1990-10-09 | 1995-11-22 | エム・ディ・リサーチ株式会社 | ペプチド又は蛋白質の製造方法 |
| ATE254179T1 (de) * | 1990-11-29 | 2003-11-15 | Agronomique Inst Nat Rech | Neue type-i-interferon varianten, ihre verfahren zur herstellung, und ihre verwendungen |
| US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5540923A (en) * | 1991-12-06 | 1996-07-30 | Landsforeningen Til Kraeftens Bekaemplse | Interferon proteins |
| US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
| ATE359824T1 (de) | 1992-07-31 | 2007-05-15 | Genentech Inc | Wässrige formulierung enthaltend menschliches wachstumshormon |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| US5932780A (en) | 1994-02-28 | 1999-08-03 | Yissum Research Development Company Of Hebrew University Of Jerusalem | Transgenic non-human animal assay system for anti-cholinesterase substances |
| GB9404270D0 (en) | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
| US5695750A (en) * | 1994-11-25 | 1997-12-09 | The United States Of America As Represented By The Secretary Of The Army | Compositions for use to deactivate organophosphates |
| US5480640A (en) * | 1995-05-02 | 1996-01-02 | Schering Corporation | Alpha interferon for treating prostate cancer |
| US6001625A (en) * | 1995-05-19 | 1999-12-14 | The United States Of America As Represented By The Secretary Of The Army | Site-directed mutagenesis of esterases |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| JP2000506865A (ja) * | 1996-03-14 | 2000-06-06 | ジ イミューン リスポンス コーポレイション | インターフェロンをコードする遺伝子の標的を定めた送達 |
| AU7364696A (en) | 1996-09-18 | 1998-04-14 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like genes |
| WO2001079444A2 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc | Albumin fusion proteins |
| DK1724284T3 (da) * | 2000-12-07 | 2009-11-02 | Lilly Co Eli | GLP-1 fusionsproteiner |
| US7070973B2 (en) * | 2000-12-26 | 2006-07-04 | Board Of Regents Of The University Of Nebraska | Butyrylcholinesterase variants and methods of use |
| AU2002248256B2 (en) * | 2000-12-26 | 2006-09-28 | Applied Molecular Evolution, Inc. | Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use |
| US6989261B2 (en) * | 2001-12-20 | 2006-01-24 | Eli Lilly And Company | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| US7049121B2 (en) * | 2001-12-20 | 2006-05-23 | Applied Molecular Evolution | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| CA2484556A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP2277888A3 (en) * | 2001-12-21 | 2011-04-27 | Human Genome Sciences, Inc. | Fusion proteins of albumin and erythropoietin |
| EP1458860A2 (en) * | 2001-12-21 | 2004-09-22 | Nexia Biotechnologies, Inc. | Production of butyrylcholinesterases in transgenic mammals |
| US20060253913A1 (en) * | 2001-12-21 | 2006-11-09 | Yue-Jin Huang | Production of hSA-linked butyrylcholinesterases in transgenic mammals |
| EP1594530A4 (en) * | 2003-01-22 | 2006-10-11 | Human Genome Sciences Inc | HYBRID PROTEINS OF ALBUMIN |
| PL1729795T3 (pl) | 2004-02-09 | 2016-08-31 | Human Genome Sciences Inc | Białka fuzyjne albuminy |
| US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
| AU2006280312A1 (en) | 2005-08-12 | 2007-02-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2562249A1 (en) * | 2005-10-20 | 2007-04-20 | University Of Ottawa Heart Institute | Anf analogue |
| US8334365B2 (en) * | 2006-06-07 | 2012-12-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
-
2007
- 2007-10-31 US US11/932,823 patent/US20080194481A1/en not_active Abandoned
-
2008
- 2008-10-30 AU AU2008319332A patent/AU2008319332B2/en active Active
- 2008-10-30 WO PCT/US2008/012306 patent/WO2009058322A1/en not_active Ceased
- 2008-10-30 EP EP08843705A patent/EP2211888A4/en not_active Withdrawn
- 2008-10-30 CA CA2703943A patent/CA2703943A1/en not_active Abandoned
- 2008-10-30 JP JP2010532056A patent/JP2011501959A/ja active Pending
-
2010
- 2010-04-06 IL IL204839A patent/IL204839A0/en unknown
- 2010-06-03 US US12/793,658 patent/US8287859B2/en not_active Expired - Lifetime
-
2013
- 2013-11-11 JP JP2013233069A patent/JP5856131B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011501959A5 (enExample) | ||
| CN101389648B (zh) | 肽胃泌酸调节素衍生物 | |
| TWI760333B (zh) | Ｇｄｆ１５融合蛋白及其用途 | |
| CN101367873B (zh) | 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用 | |
| JP6121330B2 (ja) | 作用持続時間が増した改変ポリペプチド | |
| CN103547590B (zh) | 高度可溶性瘦蛋白 | |
| CN102197049B (zh) | 胰岛淀粉样多肽衍生物 | |
| EP2094288A2 (en) | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage | |
| CN108473546B (zh) | Mg53突变体及其制备方法和用途 | |
| CN102153652A (zh) | 一种融合蛋白的表达方法及用途 | |
| JP2007521807A5 (enExample) | ||
| JP2013536254A (ja) | インターロイキン−２２のウイルス性肝炎の治療における応用 | |
| CN106432509B (zh) | 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用 | |
| CN101240033B (zh) | 一种促胰岛素分泌肽与人血清白蛋白的融合蛋白及其制备方法 | |
| JP2012511506A (ja) | 新規インスリンアナログ | |
| US8008257B2 (en) | ANF fusion proteins | |
| WO1997038014A1 (en) | Fibulin pharmaceutical compositions and related methods | |
| JP6612360B2 (ja) | 薬用作用を有する融合タンパク質複合体および融合タンパク質 | |
| JP2013520166A5 (enExample) | ||
| KR102700862B1 (ko) | apoC-II 모방 펩타이드 | |
| CN1320117C (zh) | 脂联素－胰升糖素样肽－1类似肽融合蛋白表达载体及构建 | |
| JP2024517967A (ja) | 修飾ｂ型ナトリウム利尿ペプチド | |
| CN103159847A (zh) | 一种利钠肽及其基因与用途 | |
| RU2369404C2 (ru) | Слитые белки альбумина | |
| CN103601808A (zh) | 新型钠肽、制备方法及其在制备基因工程药物中的应用 |